Welcome to our dedicated page for Privia Health Group SEC filings (Ticker: PRVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Privia Health Group, Inc. (Nasdaq: PRVA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Privia Health is a Delaware-incorporated, technology-driven physician enablement company based in Arlington, Virginia, and its filings offer detailed information about its financial condition, operations, governance, and material events.
Among the most frequently referenced documents are current reports on Form 8-K, which Privia Health uses to announce quarterly financial results, guidance updates, and other significant developments. For example, the company has filed 8-Ks to furnish press releases covering its first, second, and third quarter results, including metrics such as total revenue, net income, Adjusted EBITDA, Implemented Providers, Value-Based Care Attributed Lives, Practice Collections, Care Margin, and Platform Contribution. It has also filed 8-Ks to describe material events like the definitive agreement to acquire an Accountable Care Organization business from Evolent Health, Inc., and changes in its Board of Directors.
Investors analyzing PRVA can use annual reports on Form 10-K and quarterly reports on Form 10-Q (when available through EDGAR) to review segment information, risk factors, non-GAAP reconciliations, and detailed discussions of the company’s value-based care model and physician enablement platform. These filings also elaborate on regulatory risks, relationships with medical groups and providers, and dependencies on key technology vendors.
On Stock Titan, Privia Health filings are complemented by AI-powered summaries that explain the key points of lengthy documents such as 10-Ks and 10-Qs, and highlight notable items in 8-Ks. Users can quickly see what changed from prior periods, how management describes performance in value-based care programs like the Medicare Shared Savings Program, and where guidance or risk disclosures have been updated. The platform also surfaces relevant insider and governance-related filings, helping readers track board appointments, compensation plans, and other corporate actions disclosed to the SEC.
David Mountcastle filed a Form 144 reporting proposed sales of Common Stock of PRVA. The filing lists multiple sale entries tied to open-market dispositions and a separate restricted stock vesting on 04/01/2026.
Reported sale examples include 5,361 shares on 02/26/2026 for $134,030.87 and 7,697 shares on 02/27/2026 for $192,798.08, with additional sales in March 2026.
Privia Health Group, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 20, 2026 at 11:00 a.m. Eastern Time. Proposals include electing three Class I directors to terms ending in 2029, an advisory “say‑on‑pay” vote on named executive officer compensation, and ratifying PricewaterhouseCoopers LLP as independent auditor for 2026.
The Board remains classified into three staggered classes and currently has nine directors, most of whom are independent and serve on key committees covering audit, compensation, nominating and governance, and compliance. The company highlights stockholder outreach, strong governance policies such as anti‑hedging and anti‑pledging rules, a robust insider trading policy, and broad ESG, cybersecurity, and talent management initiatives.
Privia Health Group Inc: The Vanguard Group filed a Schedule 13G/A amendment reporting 0 shares and 0% beneficial ownership of Privia Health common stock. The filing explains an internal realignment on January 12, 2026 that led to disaggregated reporting by Vanguard subsidiaries. The form lists Vanguard's business address and is signed on 03/27/2026 by Ashley Grim, Head of Global Fund Administration.
Privia Health Group EVP & Chief Financial Officer David Mountcastle reported an open-market sale of 6,391 shares of common stock at $22.11 per share. According to the footnote, this was a nondiscretionary sale-to-cover transaction required to satisfy tax withholding obligations tied to vesting performance stock units.
After the sale, he held 220,413 shares directly and 8,695 shares indirectly through his spouse, indicating that the sale represents a small portion of his overall ownership and is linked to equity compensation tax requirements rather than a discretionary portfolio move.
Privia Health Group, Inc. Chief Executive Officer Parth Mehrotra reported a sale of 26,509 shares of common stock on March 16, 2026 at an average price of $22.11 per share. According to the disclosure, this was a nondiscretionary sale to cover tax withholding obligations related to vesting and settlement of performance stock units. After the transaction, Mehrotra directly holds 555,443 shares of Privia Health Group common stock.
Privia Health Group EVP & CFO David Mountcastle reported routine share dispositions tied to tax withholding. On March 13, 2026, he sold 6,565 shares of common stock at $21.52 per share, and on March 12, 2026, he sold 6,453 shares at $21.90 per share in open-market transactions. A footnote explains these were nondiscretionary “sell to cover” transactions required to satisfy tax withholding obligations from the vesting and settlement of performance stock units. After these transactions, he held 226,804 shares directly and 8,695 shares indirectly through his spouse.
Privia Health Group, Inc. Chief Executive Officer Parth Mehrotra reported two transactions involving company common stock. On March 12, he sold 26,763 shares at $21.90 per share, followed by a sale of 27,229 shares at $21.52 per share on March 13. A footnote explains these sales were nondiscretionary sell-to-cover transactions required to satisfy tax withholding obligations tied to the vesting and settlement of performance stock units, rather than elective portfolio moves. After the second transaction, Mehrotra directly held 581,952 shares of Privia Health Group common stock.
Parth Mehrotra reported planned sales of Common Stock. The Form 144 lists sales on 03/06/2026 (21,440 shares, $496,357.44), 03/09/2026 (41,999 shares, $960,197.55), 03/10/2026 (21,097 shares, $479,144.34), 03/12/2026 (26,763 shares, $586,096.32), and 03/13/2026 (27,229 shares, $586,096.06).
The filing also shows a restricted stock vesting on 03/13/2026 of 26,509 shares reported as compensation. Broker information lists Fidelity Brokerage Services LLC for transactions on 03/16/2026.
PRVA notice under Rule 144 reporting planned/resumed sales of Common Stock and recent dispositions by an affiliated holder. The filing lists a restricted stock vesting delivery of 6,391 shares on 03/13/2026 as compensation and multiple sales by David Mountcastle during Feb–Mar 2026 with dated share quantities and proceeds.